First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras
Sponsor: Brown University
Terminated
possible lack of efficacy
Other terminated trials from Brown University
Other Colorectal Cancer trials with similar outcome
This PHASE2 trial investigates Colorectal Cancer and is currently terminated or withdrawn. Brown University leads this study, which shows 11 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2019 — Mar 2020 [monthly]
Terminated PHASE2
-
Apr 2019 — May 2019 [monthly]
Terminated PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brown University
- Rhode Island Hospital
- The Miriam Hospital
For direct contact, visit the study record on ClinicalTrials.gov .